Allergan racked up another indication for Botox (onabotulinumtoxinA) – known mostly for its antiwrinkle capabilities – this time to treat overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency and frequency but are unable to use or have had an inadequate response to anticholinergics.
Allergan racked up another indication for Botox (onabotulinumtoxinA) – known mostly for its antiwrinkle capabilities – this time to treat overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency and frequency but are unable to use or have had an inadequate response to anticholinergics.
The latest win makes it the eighth medical indication for Botox in the US, the Irvine, California-based company said.
Multi-blockbuster falls short in a giant cell arteritis study.
Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.
Lilly-rejected candidate impresses in Phase IIb atopic dermatitis trial.
Once-daily oral FASN inhibitor denifanstat meets all endpoints in a Chinese Phase III trial for moderate-to-severe acne, paving the way for a regulatory submission in China.
The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.
Data from a second pivotal trial support a filing in the US for Opus Genetics’ phentolamine ophthalmic solution, to treat presbyopia.
The company announced plans to move an oral GLP-1/GIP/GCG receptor agonist peptide into clinical development for obesity in 2026.
